Oct 15
Too much of a good thing? A flood of data is slowing clinical trials.
10/15/2025
In an industry driven by scientific curiosity and innovation, the notion that too much data could be a drawback is almost blasphemy. But with a single phase 3 trial now generating nearly six million data points, it may be time to pare down protocols, according to a new study.
Read the full article by PharmaVoice here.
Related Blog Posts
From Vision to Value: A Blueprint for Implementing Industry Consortia Innovations
Our healthcare landscape is rapidly evolving and presenting us with complex challenges: modernizing clinical trials, ethically integrating artificial intelligence, and delivering patient-centric care. No single organization can tackle these issues alone. Read the full article from DIA Global Forum here.
TransCelerate Highlights Digital Momentum and Global Collaboration in 2025 Annual Report
TransCelerate BioPharma has released its 2025 annual report, titled The Power of Forward, outlining a year defined by continued digital adoption, regulatory collaboration, and expansion of pragmatic approaches to clinical development. Read the full article featuring Janice Chang from Applied Clinical Trials here.
When Friction Meets Force in Clinical Research
More than a decade ago, a group of pharma R&D heads gathered for an annual meeting focused on addressing common industry challenges. They had a running joke: With an average tenure of just three years, if they wanted to see each other at more than one of these gatherings, they’d better figure out how to…